Functional imaging in Parkinson's disease and dementia with Lewy bodies

Journal of Geriatric Psychiatry and Neurology

Volumn 17, Issue 3, 2004, Pages 158-163

  Colloby, Sean ^a   O'Brien, John ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Dementia; Lewy bodies; Parkinson's disease

Indexed keywords

LEVODOPA; ROPINIROLE;

BRAIN FUNCTION; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ESSENTIAL TREMOR; HUMAN; IMAGING; LEWY BODY; NEUROPSYCHIATRY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HUMANS; LEWY BODY DISEASE; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 4344597849     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/0891988704267468     Document Type: Review

References (59)

1. Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson's disease with F-18 fluorodeoxyglucose and positron emission tomography. Neurology 1995; 45:1995-2004.
2. Mohr E, Mann UM, Miletich RS, et al. Neuropsychological and glucose metabolic profiles in asymmetric Parkinson's disease. Can J Neurol Sci 1992; 19:163-169.
3. Wolfson LI, Leenders KL, Brown LL, Jones T. Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease. Neurology 1985; 35:1399-1405.
4. Berding G, Odin P, Brooks DJ, et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with F-18 FDG-PET. Mov Disord 2001; 16:1014-1022.
5. Ito K, Morrish PK, Rakshi JS, et al. Statistical parametric mapping with F-18-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 66:754-758.
6. Lucignani G, Gobbo C, Moresco RM, et al. The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using C-11-2-beta-carbomethoxy-3-beta-(4-fluorophenyl)-tropane in patients with movement disorders. Nucl Med Commun 2002; 23:1047-1055.
7. Ma Y, Dhawan V, Mentis M, Chaly T, Spetsieris PG, Eidelberg D. Parametric mapping of F-18 FPCIT binding in early stage Parkinson's disease: a PET study. Synapse 2002; 45:125-133.
8. Rinne JO, Nurmi E, Ruottinen HM, Bergman J, Eskola O, Solin O. F-18 FDOPA and F-18 CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. Synapse 2001; 40:193-200.
9. Antonini A, De Notaris R, Benti R, De Gaspari D, Pezzoli G. Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. Neurol Sci 2001; 22:45-46.
10. Markus HS, Costa DC, Lees AJ. HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness. J Neurol Neurosurg Psychiatry 1994; 57:180-185.
11. Tachibana H, Tomino Y, Kawabata K, Sugita M, Fukuchi M. 12-month follow-up study of regional cerebral blood flow in Parkinson's disease. Dementia 1995; 6:89-93.
12. Jagust WJ, Reed BR, Martin EM, Eberling JL, Nelsonabbott RA. Cognitive function and regional cerebral blood flow in Parkinson's disease. Brain 1992; 115:521-537.
13. Abe Y, Kachi T, Kato T, et al. Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing. J Neurol Neurosurg Psychiatry 2003; 74:419-422.
14. Firbank M, Colloby SJ, Burn D, McKeith IG, O'Brien JT. Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage 2003; 20:1309-1319.
15. Imon Y, Matsuda H, Ogawa M, Kogure D, Sunohara N. SPECT image analysis using statistical parametric mapping in patients with Parkinson's disease. J Nucl Med 1999; 40:1583-1589.
16. Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000; 15:503-510.
17. Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. J Nucl Med 1999; 40:753-761.
18. Booij J, Tissingh G, Boer GJ, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62:133-140.
19. Habraken JB, Booij J, Slomka P, Sokole EB, van Royen EA. Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. J Nucl Med 1999; 40:1091-1097.
20. O'Brien JT, Colloby SJ, Fenwick J, et al. Dopamine transporter loss visualised with FP-CIT SPECT in dementia with Lewy bodies. Arch Neurol In press.
21. Seibyl JP, Marek K, Sheff K, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998; 39:1500-1508.
22. Sjoholm H, Sundsfjord J, Mellgren SI. Beta-CIT-SPECT combined with UPDRS appears to distinguish different parkinsonian conditions. Acta Neurol Scand 2002; 105:5-7.
23. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. I-123 beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 2001; 16:1023-1032.
24. Walker Z, Costa DC, Walker RWH, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002; 73:134-140.
25. Brucke T, Podreka I, Angelberger P, et al. Dopamine-D2 receptor imaging with SPECT studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991; 11:220-228.
26. Oyanagi C, Katsumi Y, Hanakawa T, et al. Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using 1-123 iodobenzofuran single-photon emission computed tomography. J Neuroimaging 2002; 12:316-324.
27. Tatsch K, Schwarz J, Oertel WH, Kirsch CM. SPECT imaging of dopamine D2 receptors with 1-123 IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Commun 1991; 12:699-707.
28. Laulumaa V, Kuikka JT, Soininen H, Bergstrom K, Lansimies E, Riekkinen P. Imaging of D2 dopamine receptors of patients with Parkinson's disease using single photon emission computed tomography and iodobenzamide I123. Arch Neurol 1993; 50:509-512.
29. Firbank MJ, Harrison RM, O'Brien JT. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement Geriatr Cogn Disord 2002; 14:64-76.
30. Camicioli RM, Korzan JR, Foster SL, et al. Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neurosci Lett 2004; 354:177-180.
31. Elsinger CL, Rao SM, Zimbelman JL, Reynolds NC, Blindauer KA, Hoffmann RG. Neural basis for impaired time reproduction in Parkinson's disease: an fMRI study. J Int Neuropsychol Soc 2003; 9:1088-1098.
32. Tambasco N, Lalli F, Rossi A, Gallai V, Guercini G, Pelliccioli GP. Activation of cortical motor areas in Parkinson's disease: a functional magnetic resonance study. Riv Neuroradiol 2000; 13:105-109.
33. Haslinger B, Erhard P, Kampfe N, et al. Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. Brain 2001; 124:558-570.
34. Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 2003; 23:6351-6356.
35. Albin RL, Minoshima S, Damato CJ, Frey KA, Kuhl DA, Sima AAF. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996; 47:462-466.
36. Higuchi M, Tashiro M, Arai H, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 2000; 162:247-256.
37. Imamura T, Ishii K, Sasaki M, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography. Neurosci Lett 1997; 235:49-52.
38. Ishii K, Imamura T, Sasaki M, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 1998; 51:125-130.
39. Hu XS, Okamura N, Arai H, et al. F-18-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 2000; 55:1575-1576.
40. Colloby SJ, Fenwick JD, Williams ED, et al. A comparison of Tc-99m-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging 2002; 29:615-622.
41. Donnemiller E, Heilmann J, Wenning GK, et al. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997; 24:320-325.
42. Ishii K, Yamaji S, Kitagaki H, Imamura T, Hirono N, Mori E. Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology 1999; 53:413-416.
43. Defebvre LJ, Leduc V, Duhamel A, et al. Technetium HMPAO SPECT study in dementia with Lewy bodies, Alzheimer's disease and idiopathic Parkinson's disease. J Nucl Med 1999; 40:956-962.
44. Molina JA, Garcia-Segura JM, Benito-Leon J, et al. Proton magnetic resonance spectroscopy in dementia with Lewy bodies. Eur Neurol 2002; 48:158-163.
45. Burton EJ, Karas G, Paling SM, et al. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 2002; 17:618-630.
46. Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brucke T. I-123 beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998; 105:1213-1228.
47. Marek K, Seibyl J, Holloway R, et al. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 2000; 55:1540-1547.
48. Nurmi E, Ruottinen HM, Bergman J, et al. Rate of progression in Parkinson's disease: a 6-[18F] fluoro-L-dopa PET study. Mov Disord 2001; 16:608-615.
49. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996; 119:585-591.
50. Kaasinen V, Aalto S, Nagren K, Hietala J, Sonninen P, Rinne JO. Extrastriatal dopamine D-2 receptors in Parkinson's disease: a longitudinal study. J Neural Transm 2003; 110:591-601.
51. Marek K, Innis R, van Dyck C, et al. 1-123 beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001; 57:2089-2094.
52. Pirker W, Djamshidian S, Asenbaum S, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 2002; 17:45-53.
53. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC. I-123 beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74:294-298.
54. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54:93-101.
55. Rakshi JS, Pavese N, Uema T, et al. A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an F-18-dopa PET study. J Neural Transm 2002; 109:1433-1443.
56. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D-1 and D-2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997; 49:717-723.
57. Schwarz J, Tatsch K, Arnold G, et al. I-123 iodobenzamide SPECT predicts dopaminergic responsiveness in patients with denovo parkinsonism. Neurology 1992; 42:556-561.
58. Schwarz J, Tatsch K, Gasser T, Arnold G, Oertel WH. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. Mov Disord 1997; 12:898-902.
59. Schwarz J, Tatsch K, Gasser T, et al. I-123-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord 1998; 13:16-19.